-
Study aim
-
Determine the effect of oral taurine supplementation on serum levels of fibroblast growth factors ( FGF19, FGF21), β-Klotho co-receptor, glycemic status, lipid profile, adipocytokines, hs-CRP and body composition
-
Design
-
This is a double-blind, parallel-group, randomized controlled clinical trial
-
Settings and conduct
-
This study will be carried out by referring to private nutrition clinics in Ahvaz city. Individuals in the intervention and control group will receive 3 grams of Taurine daily in the form of capsules or placebo for 2 months, respectively. Each person will fill the individual consent, physical activity and 24-hour recall questionnaires. At the beginning and the end of the study, fasting blood samples are taken from 5 mL blood donors. energy needs will calculate by Mifflin Jeor St equation. Then, 30% of estimated energy requirements will deduct.
-
Participants/Inclusion and exclusion criteria
-
Eligibility criteria: women aged 18 to 50 years old and body mass index (BMI) between 30 to 40;
Non eligibility criteria: menopause, pregnancy and breastfeeding, having history of food allergy, cancer, acute or chronic renal failure, acute or chronic hepatic failure, thyroid disorder and gastrointestinal diseases, having surgical operation for weight loss, having weight loss over the past six months ,consumption of multivitamin/mineral or herbal supplements and weight-loss drugs,having a special diet.
-
Intervention groups
-
1) placebo group + a standard hypocaloric diet
2) taurine supplementation group + a standard hypocaloric diet
-
Main outcome variables
-
FGF19, FGF21, β-Klotho co-receptor, glycemic status, lipid profile, adipocytokines, hs-CRP and body composition